BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis 2021;73:755-7. [PMID: 34492699 DOI: 10.1093/cid/ciab718] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Dureja C, Olaitan AO, Hurdle JG. Mechanisms and impact of antimicrobial resistance in Clostridioides difficile. Current Opinion in Microbiology 2022;66:63-72. [DOI: 10.1016/j.mib.2022.01.004] [Reference Citation Analysis]
2 Alonso CD, Maron G, Kamboj M, Carpenter PA, Gurunathan A, Mullane K, Dubberke ER. American Society for Transplantation and Cellular Therapy Series: #5 - Management of Clostridioides difficile infection in hematopoietic cell transplant recipients. Transplant Cell Ther 2022:S2666-6367(22)00093-8. [PMID: 35202891 DOI: 10.1016/j.jtct.2022.02.013] [Reference Citation Analysis]
3 Kraft C, Mehta N. Is the Ultrasensitive Toxin Immunoassay the Solution to the Goldilocks Problem of Clostridioides difficile Diagnostics? Clin Infect Dis 2021:ciab833. [PMID: 34537826 DOI: 10.1093/cid/ciab833] [Reference Citation Analysis]
4 Johnson TM, Molina KC, Howard AH, Schwarz K, Allen L, Huang M, Bajrovic V, Miller MA. Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence. Clin Infect Dis 2021:ciab674. [PMID: 34665248 DOI: 10.1093/cid/ciab674] [Reference Citation Analysis]
5 Sattler MM, Crews JD. Challenges in the Diagnosis and Management of Recurrent and Severe Clostridioides difficile Infection in Children. J Pediatric Infect Dis Soc 2021;10:S27-33. [PMID: 34791399 DOI: 10.1093/jpids/piab079] [Reference Citation Analysis]
6 Piekarska A, Gil L, Mikulska M, Mensah-Glanowska P, Sbianchi G, Wendel L, Knelange N, Averbuch D, de la Camara R, Styczynski J. Discrepancies in the management of Clostridioides difficile infections in patients after allogeneic haematopoietic cell transplantation: the results of the Infectious Diseases Working Party EBMT survey. Bone Marrow Transplant 2022. [PMID: 35145219 DOI: 10.1038/s41409-022-01608-7] [Reference Citation Analysis]
7 Chandrabos C, Chin K, Liu Y, Kohn N, Swaminath A, Sultan K. Clostridiodes difficile Treatment Guided by Polymerase Chain Reaction Stool Testing Does not Alter Outcomes for Patients With Inflammatory Bowel Disease. J Clin Med Res 2021;13:572-4. [PMID: 35059077 DOI: 10.14740/jocmr4610] [Reference Citation Analysis]
8 Eubank TA, Gonzales-luna AJ, Hurdle JG, Garey KW. Genetic Mechanisms of Vancomycin Resistance in Clostridioides difficile: A Systematic Review. Antibiotics 2022;11:258. [DOI: 10.3390/antibiotics11020258] [Reference Citation Analysis]
9 Hall RG, Cole TJ, Shaw C, Alvarez CA. The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts. Antibiotics 2022;11:295. [DOI: 10.3390/antibiotics11030295] [Reference Citation Analysis]
10 Kociolek LK, Zackular JP, Savidge T. Translational Aspects of the Immunology of Clostridioides difficile Infection: Implications for Pediatric Populations. J Pediatric Infect Dis Soc 2021;10:S8-S15. [PMID: 34791392 DOI: 10.1093/jpids/piab089] [Reference Citation Analysis]